Cover Image
Market Research Report

Endometriosis Drugs Market by Product, RoA, and Geography - Global Forecast & Analysis 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 363164
Published Content info 159 Pages
Delivery time: 1-2 business days
Price
Back to Top
Endometriosis Drugs Market by Product, RoA, and Geography - Global Forecast & Analysis 2019-2023
Published: September 30, 2019 Content info: 159 Pages
Description

About this market

Technavio's endometriosis drugs market analysis considers sales from both hormone therapy and analgesics products. Our report also finds the sales of endometriosis drugs in Asia, Europe, North America, and ROW. In 2018, the hormone therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the introduction of novel drug delivery systems will play a vital role in the hormone therapy segment to maintain its market position. Also, our global endometriosis drugs market report looks at factors such as recent approvals of advanced diagnostics, rising focus on women's health, and popularity of novel drug delivery systems. However, the suppressive nature of available therapies, side effects of OCPs, and clinical trial failures may hamper the growth of the endometriosis drugs industry over the forecast period.

Overview

Rising focus on women's health

The increasing focus emphasis on women's health is expected to boost the growth of the endometriosis drugs market size during the forecast period. Lack of awareness about several gynecological cancer indications such as endometriosis and endometrial cancer was a challenge for the growth of the market. However, various governmental authorities and organizations are working to raise awareness to overcome such challengesproblems. For instance, the Office on Women's Health (OWH), which is a part of the US Department of Health and Human Services (HHS), coordinates women's health efforts and addresses critical women's health issues by informing and advancing policies and educating healthcare professionals and consumers. This focus on women's health will lead to the expansion of the global endometriosis drugs market at a CAGR of over 3% during the forecast period.

Availability of patient assistance programs

The endometriosis drug market is dominated by high-cost hormone-based therapeutics, which is a significant concern for patients. Thus, companies such as AbbVie and Bayer are providing patient-assistance programs to reduce the cost burden on patients. The availability of patient assistance programs for high-cost branded drugs will increase patient adherence to such drugsmedications, which is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global endometriosis drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global endometriosis drug market is moderately fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading endometriosis drugs manufacturers, that include AbbVie Inc., Allergan Plc, AstraZeneca Plc, Bayer AG, Johnson & Johnson Services Inc., Mayne Pharma Group Ltd., Merck & Co., Inc., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Also, the endometriosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming future growth opportunities.

Table of Contents
Product Code: IRTNTR32107

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Hormone therapy - Market size and forecast 2018-2023
  • Analgesics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: MARKET SEGMENTATION BY ROA

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Strategic alliances
  • Robust pipeline
  • Availability of patient-assistance programs

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Allergan Plc
  • AstraZeneca Plc
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Mayne Pharma Group Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Hormone therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Hormone therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Analgesics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Analgesics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Market segmentation by RoA: Overview
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Side effects of OCPs used for treatment of endometriosis
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Drug development pipeline late-stage molecules for treatment of endometriosis
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: AbbVie Inc. - Vendor overview
  • Exhibit 52: AbbVie Inc. - Business segments
  • Exhibit 53: AbbVie Inc. - Organizational developments
  • Exhibit 54: AbbVie Inc. - Geographic focus
  • Exhibit 55: AbbVie Inc. - Key offerings
  • Exhibit 56: AbbVie Inc. - Key customers
  • Exhibit 57: Allergan Plc - Vendor overview
  • Exhibit 58: Allergan Plc - Business segments
  • Exhibit 59: Allergan Plc - Organizational developments
  • Exhibit 60: Allergan Plc - Segment focus
  • Exhibit 61: Allergan Plc - Key offerings
  • Exhibit 62: Allergan Plc - Key customers
  • Exhibit 63: AstraZeneca Plc - Vendor overview
  • Exhibit 64: AstraZeneca Plc - Business segments
  • Exhibit 65: AstraZeneca Plc - Organizational developments
  • Exhibit 66: AstraZeneca Plc - Geographic focus
  • Exhibit 67: AstraZeneca Plc - Key offerings
  • Exhibit 68: AstraZeneca Plc - Key customers
  • Exhibit 69: Bayer AG - Vendor overview
  • Exhibit 70: Bayer AG - Business segments
  • Exhibit 71: Bayer AG - Organizational developments
  • Exhibit 72: Bayer AG - Geographic focus
  • Exhibit 73: Bayer AG - Segment focus
  • Exhibit 74: Bayer AG - Key offerings
  • Exhibit 75: Bayer AG - Key customers
  • Exhibit 76: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 77: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 78: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 79: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 80: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 81: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 82: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 83: Mayne Pharma Group Ltd. - Vendor overview
  • Exhibit 84: Mayne Pharma Group Ltd. - Business segments
  • Exhibit 85: Mayne Pharma Group Ltd. - Organizational developments
  • Exhibit 86: Mayne Pharma Group Ltd. - Geographic focus
  • Exhibit 87: Mayne Pharma Group Ltd. - Segment focus
  • Exhibit 88: Mayne Pharma Group Ltd. - Key offerings
  • Exhibit 89: Mayne Pharma Group Ltd. - Key customers
  • Exhibit 90: Merck & Co. Inc. - Vendor overview
  • Exhibit 91: Merck & Co. Inc. - Business segments
  • Exhibit 92: Merck & Co. Inc. - Organizational developments
  • Exhibit 93: Merck & Co. Inc. - Geographic focus
  • Exhibit 94: Merck & Co. Inc. - Segment focus
  • Exhibit 95: Merck & Co. Inc. - Key offerings
  • Exhibit 96: Merck & Co. Inc. - Key customers
  • Exhibit 97: Pfizer Inc. - Vendor overview
  • Exhibit 98: Pfizer Inc. - Business segments
  • Exhibit 99: Pfizer Inc. - Organizational developments
  • Exhibit 100: Pfizer Inc. - Geographic focus
  • Exhibit 101: Pfizer Inc. - Segment focus
  • Exhibit 102: Pfizer Inc. - Key offerings
  • Exhibit 103: Pfizer Inc. - Key customers
  • Exhibit 104: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 105: Takeda Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 106: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 107: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 108: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 116: Validation techniques employed for market sizing
  • Exhibit 117: Definition of market positioning of vendors
Back to Top